China Biotech Group is the controlling shareholder of Beijing Bioproducts Research Institute and the ultimate controller of Tiantan Bio. After the completion of the gratuitous transfer, Tiantan Bio was promoted from a grandson company of China Biotech Group to a subsidiary. So far, the company's de facto controller China Biotechnology Group Corp. holds 183.15 million shares of Tiantan Biological, accounting for 56.27% of the company's total share capital, Tiantan Biological become the largest shareholder.
Tiantan Bio, a listed company, has repeatedly released announcements that China National Biotechnology Group Corp. has formed a working group for overall listing, and will gradually integrate the internal business of the group's system and optimize the allocation of resources in the near future by means of directional issuance, acquisition of assets and merger by absorption, etc. The overall plan is to inject its six biological research institutes into Tiantan Bio to set up a micro-valley bio-national vaccine center. Beijing Research Institute of Biological Products, founded in 1919, is China's earliest unit engaged in microbiology, immunology research and production of vaccination products, formerly directly under the management of the Ministry of Health, now covers an area of 560,000 square meters, with a building area of 110,000 square meters. There are 1,473 employees, including 612 scientific and technical personnel, accounting for 42% of the total number of employees. Among them, 88 are senior technicians and 170 are middle-level technicians. The Institute is not only the first to develop important research projects and the first to successfully develop and popularize the use of important anti-epidemic products, but also the early research unit of antimicrobials in China. The Institute produces a variety of epidemic prevention products, blood products and diagnostic supplies, which have made outstanding contributions to the prevention, control and reduction of infectious diseases, improvement of people's health and prolongation of people's life.
The late Professor Tang Feifan was the first to successfully isolate Chlamydia trachomatis in the world, and was awarded the Gold Medal by the International Trachoma Organization; the blood-borne Hepatitis B vaccine, which was the first to be successfully developed in China, was awarded the First Prize of the National Scientific and Technological Advancement; and there are more than 60 other scientific research achievements that have been granted by the State, the Ministry of Health, and other departments with various awards. With the development of modern bio-technology, the institute will realize the key development in the fields of genetic engineering, cell engineering, molecular biology, etc., and build an important base for the development of China's modern bio-technology products while giving full play to the advantages of traditional bio-technology.
The institute maintains close contact with many domestic and foreign research institutes and laboratories as well as the World Health Organization. Some famous international scholars and officials of the World Health Organization have visited the Institute many times, which has reached 600 times since 1978; 200 scientific and technological personnel and experts of the Institute have been sent abroad for further training, study tours or to attend international conferences. Chen Zhenren, Zhang Yihao, Su Wannian and other experts of the Institute have served as members of the Global Expanded Programme on Immunization (EPI) Advisory Group. Chengdu Institute of Biological Products is one of the largest research and production bases of biological products in China, covering an area of more than 480,000 square meters, which is subordinate to China Biotechnology Group Corporation (CBGC), an important state-owned backbone enterprise managed by State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, and has served as a collaborative center for immunization in six provinces, cities and autonomous regions of southwestern China since its establishment in 1958.
The "Rongsheng" brand series of products mainly cover five categories: First, blood products, such as human albumin, Rongsheng Jingcai, Rongsheng Yipu, etc.; second, bacterial vaccines and toxoids, such as BCG vaccine, DPT triple preparation, live vaccine against B brain, etc.; third, immune regulation, such as Kasunin, etc.; fourth, diagnostics, such as Salmonella diagnostic serum. The fourth is diagnostic products, such as Salmonella diagnostic serum, syphilis diagnostic preparation, etc.; the fifth is genetically engineered products, such as granulocyte colony-stimulating factor, genetically engineered hepatitis B vaccine, etc.. All production plants have passed the national GMP certification.
Jieyiwei (live attenuated encephalitis B vaccine), produced by Chengdu, has already protected more than 300 million Chinese children from encephalitis B. The vaccine has been used for more than 20 years in China, and has been used for more than 20 years in China. The excellent quality of this new vaccine and its successful clinical application have attracted great attention in the global vaccine field. 1997 saw the start of overseas registration of this product, and it entered the international market in 2002. 2006 saw the realization of exports to India. Many countries have expressed the hope that Chengdu Institute will become their main supplier of vaccine products.
Chengdu Rongsheng Pharmaceutical Co., Ltd, which is controlled by Chengdu Institute, specializes in the research and development, production and operation of blood products, and has created and maintained many "firsts" in China's blood products industry, and has always been in the position of the industry leader. The "Rongsheng" brand series of blood products have been praised by the Ministry of Health as "the model of blood products" and have won general praise in the market.
Chengdu Institute has strong technical force, a large number of old experts and scholars with profound academic attainments, and young scientists who are rich and strong and have mastered the modern technology to build up a strong talent cluster. Among the 800 employees of Chengdu Institute, there are nearly 130 scientific and technological personnel, more than 200 middle and senior technicians, and 27 experts enjoying government subsidies.
Chengdu Rongsheng Pharmaceutical Co., Ltd.
Chengdu Rongsheng Pharmaceutical Co., Ltd. was established on March 12, 1997 as a high-tech biopharmaceutical enterprise integrating the research and development, production and operation of blood products. It is one of the largest manufacturers of blood products in China, and its controlling shareholder is Chengdu Bioproducts Research Institute Company of China Biotechnology Group Corporation. With a registered capital of 83.261 million yuan, total assets of nearly 600 million yuan and annual sales of nearly 300 million yuan. The company has been honored by the government as "Contract and Credit Keeping Unit", "Key Advantageous Enterprise of Chengdu City", "Top Ten Enterprises of Hi-tech Zone" and so on in successive years. At present, the usage of "Rongsheng Human Albumin" has exceeded 18 million times, and the usage of "Rongsheng Jingpian" has exceeded 4 million times, and the clinical practice has fully proved their safety and effectiveness. "Rongsheng blood products are guaranteed by strict management measures in terms of quality and quality control, and are regarded as a "model of blood products" by the Ministry of Health, winning the general praise of doctors and patients.
Chengdu Institute of Biological Products, the controlling shareholder of the company, is one of the six major biological products research institutes in China, which was founded in 1953, and is an important institution engaged in the research and development of medical microbiology, immunology, cellular engineering and genetic engineering in China, and it is also the earliest enterprise in China to start the large-scale industrialized production of blood products, and one of the largest blood products production bases in China. Its Rongsheng brand blood products have occupied an undisputed dominant position in China's blood products market with comprehensive advantages of scale, quality, safety and brand, and won a high reputation in the market. 1996, Rongsheng Albumin successfully passed the tests in accordance with WHO's recommended standards and the U.S. Pharmacopoeia standards, and it was exported to North America for the first time, realizing a zero-breakthrough in China's export of blood products. Wuhan Research Institute of Biological Products, founded in 1950, was directly under the Ministry of Health of China and now belongs to China National Biotechnology Group Corporation. It is the main research institution of medical microbiology, immunology, cell engineering, genetic engineering and a large-scale hi-tech enterprise producing biological products for human beings, and it is one of the first batch of doctoral and master's degree granting sites in China, as well as a guiding center of immunization in central and southern China and one of the six main production bases of biological products in the country. It is also the guidance center for planned immunization in central and southern China and one of the six major production bases of biological products in China.
The institute has made great development in the production of biological products and scientific research, which has created a large number of experts with rich experience in biological products, including 1 WHO expert, 12 experts of the National New Drug Review Committee, 4 members of the Standardization Committee of Biological Products of the Ministry of Health, and 23 people enjoying the allowances of the state and provincial and municipal governments, and it has successively undertaken the National Research Program, The company has undertaken the National Key Program, "863" Program, "863" Youth Research Fund, National Natural Science Foundation of China, National Science and Technology Support Program, Torch Program, Spark Program, and provincial and municipal key research programs, etc., and has obtained 138 achievement awards and scientific and technological progress awards at all levels. With cell engineering, genetic engineering, biological fermentation, monoclonal antibodies, protein purification and many other high-tech and products. the establishment of the P3 laboratory further enhances the research strength of Wuhan Institute of Biological Products.
In addition to accomplishing the research and production tasks of national directive preventive biological products, the Institute is also committed to the research and development of high-tech biotechnology drugs, especially in the production of blood products, new therapeutic products and diagnostic reagents of four series, producing more than 30 kinds of products of more than a hundred specifications. Wuhan Institute of Biological Products product quality and stability, quality assurance system throughout the procurement of raw materials to finished products and product sales of the whole process, a number of major product quality has been to maintain a leading level, more than ten products have won the national and provincial, municipal quality product awards, and has obtained better economic and social benefits for China's prevention and treatment of diseases and to protect the health of the people have made significant contributions.
Since the resumption of postgraduate education in 1978, Wuhan Institute of Biological Products was the first batch of microbiology and immunology professional doctoral and master's degree-granting units approved by the State Council, and the only doctoral degree in the national bioproducts system. In the early nineties, according to the regulations of the State Education Commission, it was changed to: Immunology with the right to confer doctoral and master's degrees; Pathogenic Biology with the right to confer master's degrees. In terms of training postgraduates, we insist on the combination of scientific and technological innovation and talent cultivation, and constantly expand the enrollment scale, with more than 40 students currently enrolled. Postgraduates are educated in Tongji Medical College of Huazhong University of Science and Technology, and their scientific research projects are completed with their supervisors' institutes. Changchun Institute of Biological Products was founded in 1934 as "Hou Sheng Research Institute", which was taken over by the Northeast Anti-Japanese Democratic Alliance Army in 1946, and is a state-owned large-scale pharmaceutical and biotechnology enterprise integrating science and technology, development, production and marketing, and is an important base for the production and research of preventive, therapeutic and diagnostic biologics and high-tech products, as well as an important base for the production and research of microbiology and biotechnology in the northeast region. It is also the research center of microbiology and immunology in Northeast China, which was delinked from the Ministry of Health at the beginning of 1999 in a major change of the restructuring and reform of the ministries and commissions of the State Council, and is now under the management of China Biotechnology Group Corporation (CBGC). ***There are seven production workshops and forty-three varieties have passed the national GMP certification and received GMP certificates issued by the State Food and Drug Administration.
The Changchun Institute has strong technical force, a large number of experts and scholars with profound academic attainments lead and cultivate a group of high-level, high-quality, innovative and compound talents who actively study biopharmaceutical technology. There are 94 senior titles, more than 389 intermediate titles, more than 279 junior titles, and more than 62% of them have college degree or above. 1992 was approved by the Academic Degrees Committee of the State Council to become a master's degree-granting unit, with two professional authorization points, namely, "Medical Immunology" and "Pathogenic Biology".
The Changchun Institute is a national key biopharmaceutical backbone enterprises have undertaken the National 7th Five-Year Plan, 8th Five-Year Plan, 9th Five-Year Plan, the National High-Tech Research and Development Program (863 Program), the Torch Program, the Fund for the Research of New Drugs, the 15th Major Science and Technology Research Program, the Ministry of Science and Technology Innovation Fund Program, the revitalization of the Northeast Old Industrial Base of high-tech industrialization projects, the Provincial (Municipal) Science and Technology Development Program, and other major scientific and technological research projects. The company has been awarded one National Technology Invention Award. The company has won 1 National Technology Invention Award, 12 National Science and Technology Progress Awards, 17 National Science and Technology Conference Awards, 46 awards from national ministries and commissions, 76 national awards, and 91 provincial awards such as Provincial Science and Technology Progress Awards. It has applied for 19 national invention patents, of which 5 were authorized; 2 design patents; and 4 international invention patents.
The Changchun Institute has strong intangible assets, with 60 production approval numbers of various types, and has a unique advantage of diversified product structure in the biologics industry. Sinopharm Changchun is the first interferon pilot base in China; the first industrialized production base of Hepatitis B genetically engineered vaccine; and the first enterprise to obtain the production approval number of recombinant human interleukin-2.
Hepatitis A vaccine developed and produced by Changchun Institute is a high-tech biological product with independent intellectual property rights, which won the Second Prize of the National Scientific and Technological Progress; the Hepatitis B gene vaccine produced by Changchun Institute is a Class I New Drug of the National Biological Products. It is the first manufacturer in China to obtain an official production license for the hepatitis B genetically engineered vaccine, which has twice won the national new product award and the first prize for national scientific and technological progress.
The main products of Changchun Institute are biological products, diagnostic supplies and genetic engineering products, and the product categories include various vaccines, bacterial vaccines, toxoid, antitoxin, immune serums, blood products, cytokines, monoclonal antibodies, immunological diagnostic reagents and many other types. The main products include lyophilized live attenuated hepatitis A vaccine, influenza cracked vaccine, purified human rabies vaccine, recombinant (CHO cell) hepatitis B vaccine, epidemic hemorrhagic fever vaccine, purified forest encephalitis vaccine, anti-rabies serum and other products.
Changchun pray for health biological products limited company
Changchun pray for health biological products limited company ("pray for health biological") in September 2006 in China biotechnology group company's support, successful realization of the equity reorganization, reorganization of Beijing Tiantan Biological Products Co. Ltd, Changchun biological products research institute, China scientific equipment import and export corporation hold 51%, 39%, 10% of the shares respectively. Pray for healthy biological shareholders and all the staff *** with efforts to further optimize the company's governance structure. The company carries through "everything from communication, everything from the seriousness of doing", internal grasp of quality, external image, focusing on cooperation with the national disease control system.
Pray for the health of biological production of freeze-dried chickenpox attenuated live vaccine has been on the market for ten years. 2008, the company's products in the domestic use of a record high, and has been exported to South Korea, India and other countries. Pray for health biology is carrying out the construction of the new plant, will expand the chickenpox vaccine production scale, resume the original production of measles vaccine. Lanzhou biological products research institute was founded in 1934, its predecessor is the former national northwest epidemic prevention, is China's longest history of one of the biological products research institute. 1953 moved to the present site (lanzhou city guanzhou district salt field road 888), originally under the management of the state ministry of health. 1985, by the institutions into enterprises. 1999, under the former state economic and trade commission central enterprise work committee management. After 2002, it is under the management of State-owned Assets Management Committee of the State Council, and it is a secondary subsidiary of China National Biotechnology Group Corporation. In September 2009, China National Pharmaceutical Group Corporation and China National Biotechnology Group Corporation jointly reorganized, and it is a secondary enterprise of China National Pharmaceutical Group Corporation.
Lanzhou Institute of Biological Products is mainly engaged in the production, research and development and operation of biological products, is the backbone of the national biological products industry, is the only large-scale biological high-tech enterprises in our province and even in the northwest region; is the national medical microbiology, immunology, molecular biology, an important research institution; the Ministry of Science and Technology of the "863" program industrialization bases; the Ministry of Science and Technology of China, the "863" program industrialization bases; the Ministry of Science and Technology of the United States. It is an important research institution of medical microbiology and molecular biology in China, an industrialization base of "863" plan of the Ministry of Science and Technology, a national enterprise technology center and an enterprise technology center of Gansu Province, a post-doctoral workstation set up by the Ministry of Personnel of the People's Republic of China, and a master's degree-granting institution approved by the Academic Degrees Committee of the State Council, and a designated supplier of medicines for the medical and rehabilitation of the Ministry of Civil Affairs of China in the "Tomorrow Plan". The State Food and Drug Administration, China Pharmaceutical and Biological Products Inspection and Quarantine Institute training base. In April 2009, it was awarded the "National May 1st Labor Certificate" by the All-China Federation of Trade Unions.
Lanzhou Institute of Biological Products covers an area of 430,000 square meters, with total assets of more than 1.373 billion yuan, and achieved sales revenue of 797 million yuan in 2008, realizing a profit of 312 million yuan. The scale of assets, sales revenue and realized profits and taxes are ranked first in the province's biomedical industry. There are 1400 employees, including more than 650 technicians of various types, accounting for 46% of the total number of employees; more than 800 people with secondary school education or above, accounting for 57% of the total number of employees, and the realized profit is listed in the 17th place of the national pharmaceutical industry industrial enterprises.
Lanzhou Institute of Biological Products has established a perfect quality assurance system, all workshops have passed the GMP certification organized by SFDA, and the annual production of all kinds of vaccines (blood products) is nearly 100 million doses, and the products are sold to all provinces, cities and autonomous regions except Taiwan, which provides a solid guarantee for the health of people of all ethnic groups across the country.
Lanzhou Institute of Biological Products has six specialized research laboratories, two national strain preservation centers and a biosafety laboratory. It has a team of young and middle-aged scientific and technological personnel with reasonable echelon, good quality, dedication and devotion, as well as some influential leaders in the same industry in China, and more than 120 scientific and technological personnel are engaged in biotechnology research and development full-time, including 11 researchers. After more than 70 years of efforts, the research and development work has a good foundation, forming a distinctive scientific research topics and research directions. Lanzhou Institute of Biological Products has good cooperative relationship with many domestic and international famous research institutions.
Lanzhou Institute of Biological Products has won nearly 100 scientific and technological awards at provincial and ministerial levels. In the past ten years, it has obtained 4 varieties of Class I new drugs, 8 varieties of Class II new drugs, 2 varieties of Class III new drugs, 13 varieties of Class IV new drugs and generic drugs. We have won 1 first prize and 4 second prizes for national scientific and technological progress, 2 DuPont Scientific and Technological Innovation Prizes, and 8 provincial and ministerial scientific and technological progresses. The industrialization of these scientific research results not only produces good economic benefits, but also strongly enhances the biotechnology industry in our province and Lanzhou City.
Lanzhou Institute of Biological Products independently developed botulinum toxin type A, won the second prize of the national scientific and technological progress, is China's exclusive authorized production and sale of biological products, and was issued by the South Korean KFDA certificate of registration, is China's first independent export of biological products, has been registered in nearly more than 20 countries in the international market has a good reputation. b haemophilus influenzae type b conjugate vaccine, live oral rotavirus vaccine, etc. are exclusively produced in China, and the output of Group A Group C Meningococcal Polysaccharide Bivalent Vaccine accounts for more than 80% of the national market and has been successfully sold to Africa. The output of live attenuated measles vaccine accounts for more than 70% of the national market, playing a pivotal role in realizing the goal of eliminating measles proposed by the Ministry of Health. The sales revenue of new products with independent intellectual property rights accounts for more than 80% of the total sales revenue. Founded in 1949, Shanghai Research Institute of Biological Products (SRIB) is a state-owned large-scale high-tech enterprise integrating research and development, production and operation of biological products. It is a national master's degree-granting unit specializing in biochemistry and molecular biology, pathogenic biology, and one of the first enterprises granted the right to import and export by the state, and is one of the important bases for scientific research and production of biological products in China.
Shanghai Research Institute of Biological Products has more than 1,300 employees, more than 1,000 professional and technical personnel of various types, of which more than 300 have senior and intermediate technical titles, 7 postgraduate tutors, 15 experts enjoying the national special allowance, 4 members of the National Biological Products Standardization Committee, 4 national experts on the review of new drugs, 1 expert of the WHO Biological Standardization Advisory Group. The institute has nine research laboratories, including Molecular Biology and Monoclonal Technology, Genetic Engineering Proteomics, Bacterial Polysaccharides, Molecular Viruses, Plasma Proteins and their Preparations, Biotechnology Information and Epidemiology, Diagnostic Reagents and Microecology, Comprehensive Research on Biotechnology and Laboratory Animals, etc., which are dedicated to the research and development of new products. The company has completed dozens of national scientific research tasks such as the 7th Five-Year Plan, the 8th Five-Year Plan and the 863 Research Project. We have obtained more than 100 scientific research achievements, of which more than 30 have been awarded by the State Science and Technology Commission, the Ministry of Health or the Shanghai Science and Technology Progress Award. At the end of 1980s, we developed α1b type interferon with the Institute of Virus Research of the Preliminary Institute of Science and Technology, which is the first industrialized genetically engineered therapeutic product in China, and the first class of national new drugs, and was awarded the first prize of the National Scientific and Technological Progress. Following the development of γ-type interferon, won the second prize of the National Science and Technology Progress.
Shanghai Research Institute of Biological Products (SRIBP) has more than 200 nationally approved production numbers, and its products include blood products, preventive products, genetically engineered products, and various diagnostic reagents. It has a large-scale production line of blood preparations with advanced equipment and a vaccine production building in line with the European GMP standard, and all the production workshops have passed the national GMP certification, with an annual output value of more than 1 billion yuan in 2005.In 1996 and 2000, it successively imported high-tech products such as chickenpox vaccine and influenza vaccine from Japan, and its scale of production has been continuously expanding, and its quality has reached the international advanced level, and it has won the award of "Shanghai High-tech Achievement Transformation Award". "Shanghai High-tech Achievement Transformation Project". Varicella, influenza, MMR, human albumin and other products have won the titles of "key new products" of the state and Shanghai respectively, and "famous and excellent products" of Shanghai pharmaceutical industry. The company has also established a nationwide sales network centered in East China, providing perfect technical support and after-sales service for the majority of users, and the brand "Shangsheng" enjoys a high reputation in China. China MicroValley Biomedical Co., Ltd. is a new type of research enterprise integrating scientific research and production, which is located in Beijing and financed by China Biotechnology Group Corporation, Beijing Tiantan Biological Products Company Limited, Beijing Research Institute of Biological Products and Institute of Viral Disease Prevention and Control of the Chinese Center for Disease Control and Prevention (CDC).
Beijing Weigu Bio-pharmaceutical Co., Ltd. has undertaken the establishment of the National Engineering Research Center for New Vaccines (NERC), a key project at the national level. The National Vaccine Center is the only state-level new vaccine R&D and industrialization base and service platform approved by the National Development and Reform Commission (NDRC) for the implementation of the major strategic decision of the CPC Central Committee and the State Council on the construction of an "innovative country", with the construction site located in the Beijing Economic-Technological Development Area (BDA), and with a planned floor area of 23,000 square meters and a total investment of 21,000 million yuan. The project has a planned construction area of 23,000 square meters and a total investment of 210 million yuan. The foundation stone was laid on June 29, 2009, and the project is scheduled to be fully completed in December 2010.
As a national technology research and development and engineering technology transformation platform, the National Vaccine Center is built to comply with the standards of China, the European Union and the U.S. GMP, GLP and biosafety as a guiding principle, and focuses on a number of international advanced technologies and techniques, which can undertake the engineering research and development and technical support for national and local major projects. The National Vaccine Center will build 5 pilot production units (including 3 biosafety level 2 BSL-2 areas), including virus and inactivated vaccine production units, bacterial vaccine production units, genetic engineering production units, and insect cell production units in accordance with EU GMP standards; 4 specialized laboratories (including 2 biosafety level 2 BSL-2 laboratories), including virus, bacterial, genetic engineering, and QC laboratories; and 4 specialized laboratories (including 2 BSL-2 laboratories), including virus, bacterial, genetic engineering, and QC laboratories. virus laboratory, bacterial laboratory, genetic engineering laboratory and QC laboratory; two dispensing units (live and inactivated vaccines), packaging area, experimental animal house and other supporting facilities.
Beijing Microvale Biomedical Co., Ltd.'s main goal is to apply modern biotechnology to improve traditional vaccines and solve the major technical problems in the research, development and industrialization of new vaccines, focusing on new vaccines, recombinant proteins, peptides, nucleic acids, diagnostic reagents and other biomedicine R & D and pilot production and biotechnology consulting services, etc., to provide complete engineering and industrialization services for China's new vaccine R & D and provide complete engineering and industrialization services for China's new vaccines. We provide a complete engineering and industrialization technology platform and mature advanced production processes and technologies for the research and development of new vaccines in China. The direction of scientific research and development is to apply modern biotechnology to improve traditional vaccines, to overcome technical problems in the research and development and industrialization of new vaccines, to provide a complete engineering and industrialization technology platform for the research and development of new vaccines, and to provide mature and advanced production processes and technologies. The work focuses on the R&D and pilot production of new vaccines, recombinant proteins, peptide drugs, nucleic acid drugs, diagnostic reagents and other biopharmaceuticals, as well as providing related biotechnology consulting services.
The National Vaccine Center has been listed in the National High-Tech Industry Development Project Program and the State Funding Subsidy Program, and joined the China Biotechnology Innovation Service Alliance (ABO), and has undertaken more than 10 projects, such as the Ministry of Science and Technology's "863" Project Program, Major Infectious Disease Project, Support Project Program, International Scientific and Technological Cooperation Project, and Beijing Major Special Project. The National Vaccine Center also undertakes more than 10 major special projects. In addition, the National Vaccine Center has carried out extensive exchanges and cooperation with many domestic and foreign organizations, and has reached more than 10 cooperation projects.